Pennsylvania Bio Issues Patient Impact Report on Cancer

Pennsylvania Companies Developing More Than 450 Treatments and Diagnostics for Cancer

WAYNE, Pa.--(BUSINESS WIRE)-- Pennsylvania Bio (www.pennsylvaniabio.org) today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer. This new report is the latest in the Pennsylvania Bio MedTRACK Patient Impact Report series.

The report features information on more than 300 therapeutics and diagnostics in development or awaiting approval and 140 marketed products from nearly 50 Pennsylvania companies. Companies with operations in Pennsylvania are working on treatments for more than 40 types of cancer including acute myelogenous leukemia, breast cancer, brain tumors, leukemia, prostate cancer, and solid tumors.

According to the American Cancer Society (ACS), more than 1.5 million Americans were expected to be diagnosed with cancer and 569,500 were expected to die of cancer in 2010 – that’s more than 1,500 Americans per day. In Pennsylvania, the ACS predicted that more than 75,000 Pennsylvanians would be diagnosed with cancer by the end of the year, and that cancer would be the second leading cause of death among Pennsylvanians.

“This report demonstrates that Pennsylvania’s bioscience companies are at the forefront of developing the tools to diagnose cancer earlier and the therapeutics to treat the various forms of this life-threatening disease,” said Christopher P. Molineaux, president of Pennsylvania Bio. “We are proud of the research that is taking place that demonstrates progress for patients, not only in Pennsylvania, but around the world.”

The data for the Patient Impact Reports was compiled using the Pennsylvania Bio MedTRACK Database. Not all of the research captured in the report is happening within the borders of the Commonwealth of Pennsylvania, but it is being conducted through companies that have significant operations in the commonwealth.

Other reports in the Pennsylvania Bio MedTRACK Patient Impact Report series may be downloaded from the Media Center section of www.pennsylvaniabio.org.

About Pennsylvania Bio

Pennsylvania Bio is a catalyst to ensure Pennsylvania is a global leader in the biosciences through a cohesive community that unites the region's biotechnology, pharmaceutical, research and financial strengths. For more information, visit www.pennsylvaniabio.org.

About the Pennsylvania Bio MedTRACK Database

Pennsylvania Bio has partnered with Life Science Analytics to provide its members access to the Pennsylvania Bio MedTRACK Database. This database provides comprehensive information on public and private bioscience companies in Pennsylvania through a proven corporate intelligence tool. Members of the media may request access to this database by e-mailing Amber van Niekerk at [email protected].



CONTACT:

Pennsylvania Bio
Amber van Niekerk
Office: 610-947-6800 ext. 211
Cell: 215-520-5035
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.